1 / 27

Acquired Resistance Patient Forum

Combinations for Treating EGFR Acquired Resistance. Melissa L. Johnson, MD. Acquired Resistance Patient Forum. In ALK, ROS1 & EGFR Lung Cancers. September 6, 2014 | Boston. Combination Treatments for EGFR Acquired Resistance. Dx : EGFR+ lung cancer. Acquired Resistance.

steffi
Télécharger la présentation

Acquired Resistance Patient Forum

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Combinations for Treating EGFR Acquired Resistance Melissa L. Johnson, MD Acquired Resistance Patient Forum In ALK, ROS1 & EGFR Lung Cancers September 6, 2014 | Boston

  2. Combination Treatments for EGFR Acquired Resistance Dx: EGFR+ lung cancer Acquired Resistance Tarceva + NEW DRUG Tarceva Gilotrif Gilotrif + NEW DRUG

  3. Combination Treatments for EGFR Acquired Resistance Can we make 1st Gen TKI Better? • We have tried!! • Selected approaches to enhancing EGFR TKI in order to overcome or prevent resistance Erlotinib + Chloroquine Erlotinib + Sirolimus Erlotinib + Onartuzumab (anti-Met) Erlotiinb + Entinostat Erlotinib + R1507 (anti IGF-1) Erlotinib + Tivantinib Erlotinib + Sorafanib Erlotinib + Dasatinib Erlotinib + MK2206 (AKT) Erlotinib + MM-121 (anti-ErbB3) Erlotinib + XL184 Erlotinib + Rilotumumab (anti-HGF) • Erlotinib + Patritumumab (anti-ErbB3) • Erlotinib + AUY-922 (HSP 90 inhibitor) Slide adapted, courtesy of Thomas J. Lynch, Jr., MD

  4. Combination Treatments for EGFR Acquired Resistance Dx: EGFR+ lung cancer Acquired Resistance Tarceva/Gilotrif (erlotinib/afatinib) Tarceva/Gilotrif (erlotinib/afatinib) + NEW DRUG

  5. Combination Treatments for EGFR Acquired Resistance Flare associated with shorter TTP • 14 of 61 patients (23%, 95% CI 14-35%) had a disease flare (hospitalization or death) • Median time from last TKI to flare was 8 days (range 3-21 days) • 3 patients went on to trial treatment Chaft, Clin Cancer Res 2011

  6. Combination Treatments for EGFR Acquired Resistance AUY922: An “Onco-Chaperone” Inhibitor AUY922 (in yellow) is a synthetic isoxazole resorcinol HSP90 inhibitor, shown here bound to the deep ATP pocket of HSP90 (in blue) Neckers and Workman Clin Cancer Res 2012 AUY922+ Erlotinib Melissa L. Johnson

  7. Combination Treatments for EGFR Acquired Resistance AUY922 + Erlotinib Phase I Dose-Escalation AUY922+ Erlotinib Melissa L. Johnson

  8. HSP90 Inhibitors in Lung Adenocarcinoma Preliminary Activity Patient 01-102 AUY922 25 mg/m + Erlotinib 75 mg Duration of therapy: 6 months C1D1 C1D28 AUY922+ Erlotinib Melissa L. Johnson

  9. AUY922 + Erlotinib Phase II Study Design • Key Inclusion Criteria • Advanced lung adenocarcinoma • EGFR mutation OR previous response to EGFR TKI • EGFR TKI for ≥6 months and 1 full month prior to study start • Biopsy at time of acquired resistance to EGFR TKI Primary endpoint: Overall response rate ORR (CR + PR) Stage IV Adenocarcinoma +EGFR mutation Acquired Resistance Secondary endpoints: Progression-free survival, Overall survival, ORR in T790M+, Toxicity • Definition of Acquired Resistance19 • Previously treated with single-agent EGFR-TKI • Tumor harbors TKI-sensitive EGFR mutation (G719X, ex 19 del, L858R, L861Q) • EITHER RECIST-defined PR/CR OR ≥ 6 months clinical benefit (SD) with single-agent EGFR-TKI followed by systemic POD • Statistical Considerations: • stage I: 16 pts (if ≥2 responses, proceed to stage II) • stage II: 9 pts (if ≥ 5 responses overall, AUY922 and erlotinib are worthy of further study) • α=10%; β=10%; p0=10%; p1=30% Biopsy at resistance 30 day erlotinib lead-in Melissa L. Johnson 19 Jackman JCO 2009 • Key Exclusion Criteria • Brain metastasis that are symptomatic and/or requiring escalating doses of steroids • Systemic treatment within 4 weeks, RT within 2 weeks Erlotinib 150mg PO qday AUY922 70mg/m2

  10. Molecular Characteristics AUY922+ Erlotinib Melissa L. Johnson

  11. Best Response to AUY922 and Erlotinib N=24 Best % change in target lesions Progressive disease Stable disease Partial response EGFR T790M Partial Response (PR): 4/25 (16%)(95% CI 6-35%) Disease Control Rate (DCR): 14/25 (56%)(95% CI 37-73%) AUY922+ Erlotinib Melissa L. Johnson

  12. Individual Responses According to EGFR Mutations and Time on Primary EGFR-TKI Reason withdrawn from study * Small cell transformation patient remains on study

  13. Combination Treatments for EGFR Acquired Resistance Afatinib + Cetuximab

  14. Combination Treatments for EGFR Acquired Resistance Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR Mutant Lung Cancer with and without T790M Pathology confirmed NSCLC with EGFR mutation1 OR SD 6 months on erlotinib/gefitinib OR Partial or complete response to erlotinib/gefitinib Dose escalation schema 3–6 patients per cohort Afatinibp.o. daily + escalating doses of i.v. cetuximab q 2 weeks Dose levels starting at: afatinib 40 mg +cetuximab 250 mg/m2 Predefined maximum dose: afatinib 40 mg + cetuximab 500 mg/m2 Stop erlotinib/ gefitinib for ≥72 hours3 Disease progression2 MTD cohort expanded up to 80 EGFRmutation-positive patients4: 40 T790M+ and 40 T790M– ECOG PS 0-2 Age ≥ 18 years Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014

  15. Combination Treatments for EGFR Acquired Resistance Tumor Regression by T790M Mutation Statusat Recommended Dose Horn at al. IASLC 2011

  16. Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014

  17. Combination Treatments for EGFR Acquired Resistance Cetux/Afatanib Toxicity Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014

  18. Combination Treatments for EGFR Acquired Resistance Preliminary Efficacy Comparison

  19. Toxicity Comparison

  20. Combination Treatments for EGFR Acquired Resistance T+A vs T (#8005) Unselected Patient Population • BeTa in second line setting • ATLAS as maintenance • Both with compelling results in enriched populations of never smokers, East Asians • Possible EGFR regulation of VEGF in EGFR mutant cell lines (Heymach)

  21. Combination Treatments for EGFR Acquired Resistance JO25567Study Design • Chemotherapy-naïve • Stage IIIB/IV NSCLC or postoperative recurrence • Non-squamous • Activating EGFR mutations* • Exon 19deletion • Exon 21 L858R • Age ≥20 years • PS 0–1 • No brain metastasis EB combination Erlotinib 150mg qd + bevacizumab 15mg/kgq3w (n = 75) • Primary endpoint: PFS (RECIST v1.1, independent review) • Secondary endpoints: OS, tumor response, QoL, safety • Exploratory endpoint:biomarker assessment PD R Emonotherapy Erlotinib 150mg qd (n = 75) 1:1 PD Stratification factors: sex, smoking status, clinical stage, EGFRmutation type *T790M excluded Abstract 8005: Presented by TerufumiKato

  22. Combination Treatments for EGFR Acquired Resistance Primary endpoint: PFS by independent review 1.0 0.8 *log-ranktest, two-sided EB 0.6 E PFS probability 0.4 0.2 9.7 16.0 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 Time (months) Number at risk EB 75 72 69 64 60 53 49 38 30 20 13 8 4 4 0 E 77 66 57 44 39 29 24 21 18 12 10 5 2 1 0 Abstract 8005: Presented by TerufumiKato

  23. Combination Treatments for EGFR Acquired Resistance PFS by EGFR Mutation Type EB EB Exon 19 deletion Exon 21 L858R E E 1.0 1.0 0.8 0.8 0.6 0.6 PFS probability PFS probability 0.4 0.4 0.2 0.2 0 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 Time (months) Time (months) Number at risk Number at risk EB 40 39 38 36 33 29 27 24 19 12 8 5 2 2 0 EB 35 33 31 28 27 24 22 14 11 8 5 3 2 2 0 E 40 35 29 26 22 16 12 9 9 5 3 1 0 0 0 E 37 31 28 18 17 13 12 12 9 7 7 4 2 1 0 Abstract 8005: Presented by TerufumiKato

  24. Combination Treatments for EGFR Acquired Resistance Toxicity with Tarceva + AvastinJO25587 • No unforeseen toxicities or Rx-related deaths • Grade >3 toxicity 91% vs. 53% (esp. HTN, proteinuria) • 41% discontinued bevacizumab for adverse effects • Primarily proteinuria (15%) or hemorrhagic (12%) • Bevacizumab discontinuation rate 10-15% in BeTa, ATLAS trials

  25. EGFR + NSCLC Trials-PFS (months) Combination Treatments for EGFR Acquired Resistance Med PFS (mo) JO25587- Tarceva5 JO25587- T/A5 LUX- Lung-33 LUX- Lung-64 EURTAC1 OPTIMAL2 1. Rosell et al. Lancet Oncol. 2012;13:239;11. Zhou et al. Lancet Oncol. 2011;12:735; 3. Sequistet al. J ClinOncol. 2013;31:3327; 4. Wu et al. Lancet Oncol. 2014;15:213; 5. Kato, Proc ASCO 2014, A#8005

  26. Combination Treatments for EGFR Acquired Resistance What’s next? Akbay et al. Cancer Discovery 3:1355-1363, 2013

  27. Combination Treatments for EGFR Acquired Resistance Summary • TWICE the opportunity for success, but TWICE the side effects • Upfront or after the development of • Acquired Resistance? • Future Directions: Tarceva + PDL-1 inhibitor?

More Related